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he cell surface heparan sulfate proteoglycan
(HSPG) glypican-1 is up-regulated by pancreatic
and breast cancer cells, and its removal renders
such cells insensitive to many growth factors. We sought
to explain why the cell surface HSPG syndecan-1, which
is also up-regulated by these cells and is a known growth
factor coreceptor, does not compensate for glypican-1
loss. We show that the initial responses of these cells to
the growth factor FGF2 are not glypican dependent, but
they become so over time as FGF2 induces shedding of
syndecan-1. Manipulations that retain syndecan-1 on the
T
 
cell surface make long-term FGF2 responses glypican in-
dependent, whereas those that trigger syndecan-1 shed-
ding make initial FGF2 responses glypican dependent.
We further show that syndecan-1 shedding is mediated
by matrix metalloproteinase-7 (MMP7), which, being an-
chored to cells by HSPGs, also causes its own release in
a complex with syndecan-1 ectodomains. These results
support a specific role for shed syndecan-1 or MMP7–
syndecan-1 complexes in tumor progression and add to
accumulating evidence that syndecans and glypicans
have nonequivalent functions in vivo.
 
Introduction
 
Many growth factors use heparan sulfate proteoglycans
(HSPGs) as cofactors in receptor binding and/or signaling.
Dependence on HSPGs has been demonstrated for FGFs, hep-
arin-binding members of the EGF family, such as heparin-
binding EGF-like growth factor (HB-EGF) and the heregulins,
hepatocyte growth factor (HGF), Wnts, hedgehogs, and at least
some members of the transforming growth factor 
 

 
 superfam-
ily (Rapraeger et al., 1991; Aviezer and Yayon, 1994; Zioncheck
et al., 1995; Bellaiche et al., 1998; Tsuda et al., 1999; Li and
Loeb, 2001; Fujise et al., 2003).
The major HSPGs of the cell surface are the syndecans
and glypicans (Lander and Selleck, 2000; Perrimon and Bern-
field, 2000). The syndecans are four related transmembrane
proteins that sometimes also carry chondroitin sulfate. The
glypicans are six glycosylphosphatidylinositol (GPI)-anchored
proteins that exclusively carry heparan sulfate. We previously
reported that the expression of glypican-1 (but not other glypi-
cans) is induced in human pancreatic and breast cancer cells
and that the ability of heparin-binding growth factors to drive
the proliferation of these cells is blocked by phosphoinositide-
specific PLC (PIPLC), an enzyme that releases GPI-anchored
proteins from the cell surface (Kleeff et al., 1998; Matsuda et
al., 2001). Responsiveness can be restored with a transmem-
brane variant of glypican-1 (i.e., one that cannot be cleaved by
PIPLC). Conversely, the loss of proliferative response results
when antisense RNA is used to decrease levels of endogenous
glypican-1. Manipulation of glypican-1 levels with either PIPLC
or antisense RNA affects mitogenic responses to growth fac-
tors that are HSPG dependent, such as FGF2 and HB-EGF, but
not other growth factors such as insulin-like growth factor-1
and EGF (Kleeff et al., 1998; Matsuda et al., 2001). Inhibition
of glypican-1 expression also causes pancreatic carcinoma cell
lines to form tumors that grow more slowly in vivo (Kleeff et
al., 1999).
These studies suggest that glypican-1 plays an important
role in the development of at least some cancers. Such a strong
dependence on a glypican is surprising given that most cells
have both glypicans and syndecans and that both HSPG fami-
lies function efficiently as growth factor coreceptors (Steinfeld
et al., 1996; Zhang et al., 2001). Indeed, substantial syndecan-1
is made by both the pancreatic and breast cancer cells that are
dependent on glypican-1 for their growth factor responses
(Conejo et al., 2000; Matsuda et al., 2001). These data suggest
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that, in some circumstances at least, glypicans and syndecans
do not function equivalently. In this study, we take up the ques-
tion of why this is.
 
Results
 
Previous studies uncovered a requirement for glypican-1 in the
responses of pancreatic and breast cancer cells to several
polypeptide mitogens, including FGF2, HB-EGF, HGF, hereg-
ulin-
 

 
, and heregulin-
 

 
 (Kleeff et al., 1998, 1999; Matsuda et
al., 2001). In those studies, mitogenesis was quantified as an
increased cell number 48 h after growth factor addition. As this
endpoint is far downstream of initial growth factor signaling,
we tested for glypican dependence at earlier times. Fig. 1 A
shows that when PANC-1 pancreatic carcinoma cells are
treated with FGF2, the increase in incorporation of [
 
3
 
H]thymidine
during the first 24 h is dramatically reduced by pretreatment with
PIPLC, just as it is by pretreatment with heparinase III (which
removes heparan sulfate from the cell surface). This effect of
PIPLC was completely rescued by the expression of a trans-
membrane glypican-1 variant (Fig. 1 B).
The inhibitory effect of PIPLC on the FGF2 response was
also evident at the level of MAPK activation and there, too, could
be rescued by a transmembrane glypican-1 (Fig. 1, C and D).
In these experiments, MAPK induction was measured as the
level of phosphorylation of p42/44
 
ERK
 
 1 h after FGF exposure.
The ability of HSPGs to act as FGF coreceptors is thought
to be a function of heparan sulfate chains and independent of
core protein structure. The fact that PANC-1 cells express syn-
decan-1 (Conejo et al., 2000) but PIPLC (which removes only
GPI-anchored molecules) blocks the responsiveness to FGF2
strongly suggests that the syndecan-1 on these cells is not an
Figure 1. Glypican dependence of pancreatic
carcinoma cell responses to FGF2. (A) PANC-1
cells maintained in serum-free medium were
treated with or without 10 ng/ml FGF2 along
with [3H]thymidine for 24 h. Cultures received
1 U/ml PIPLC (third bar) or 8 mU/ml hepari-
nase III (fourth bar) 1 h before FGF addition
and throughout the remainder of the assay.
DNA was precipitated, and 3H incorporation
was measured. Data are means  SD of tripli-
cates. (B) Glyp-TM samples were two inde-
pendent clones of PANC-1 cells stably trans-
fected with a transmembrane variant of
glypican-1 (Kleeff et al., 1998). Sham-trans-
fected samples were from two independent
control PANC-1 clones transfected with vector
only. Both types of clones were assayed as in
A except that the concentration of FGF2 was
1 ng/ml. (A and B) Y axis is measured in
counts per minute. (C) One of the Glyp-TM
and one of the control clones from B were
tested for MAPK activation after exposure to 2
ng/ml FGF2 for 1 h. For the right two lanes
(PIPLC), 1 U/ml enzyme was added 1 h be-
fore FGF2 addition as well as during FGF2 in-
cubation. Cells were lysed and subjected to
Western blotting for p42/44ERK. (D) Mean val-
ues  SD (error bars) of band intensities for each of the duplicate determinations shown in C; a similar picture is obtained if the data are expressed nor-
malized to a loading control (not depicted). The reduction in MAPK activation by PIPLC in sham-transfected cells is statistically significant (P  0.05; t test).
Y axis is measured in arbitrary units. The results in A–C were also confirmed with FGF2 isolated from bovine brain (not depicted).
 
FGF coreceptor. Trivial explanations for this could be that there
is not enough syndecan-1, it is not localized to the cell surface,
or it lacks heparan sulfate. A variety of observations argue
against these possibilities, the most general of which is shown in
Fig. 2. Cells were cultured in the presence of [
 
35
 
S]sulfate, and
the release of sulfated glycosaminoglycans (GAGs) was mea-
sured in response to either PIPLC or to a mild trypsin treatment
that selectively cleaves cell surface syndecan-1, which has a
juxtamembrane protease-sensitive site, to release an intact
ectodomain (Subramanian et al., 1997). Released GAG-contain-
ing polypeptides were digested and precipitated to separately
quantify protein-bound heparan and chondroitin sulfates.
The results (Fig. 2) show that the amount of heparan
sulfate released by PIPLC is approximately the same as that
released by mild trypsinization. Moreover, after PIPLC treat-
ment, trypsin released almost as much heparan sulfate as from
cells that were not PIPLC treated (Fig. 2, second and third set
of bars). Thus, PIPLC and trypsin release nearly nonoverlap-
ping pools of cell surface heparan sulfate, with PIPLC-resistant
heparan sulfate making up at least half of the total. From this,
we conclude that on the surface of PANC-1 cells, HSPGs that
are not glypicans and that possess the trypsin sensitivity of syn-
decan-1 are at least as abundant a carrier of heparan sulfate as
are glypicans.
Although these results raised the possibility that differ-
ences in the structure of heparan sulfate on syndecan-1 versus
glypican-1 might explain their differential use as FGF corecep-
tors, an alternate explanation came to mind after we examined
the responses of PANC-1 cells to very brief FGF2 exposures.
As shown in Fig. 3, when we measured MAPK activation 15
min after FGF2 addition (a time at which p42/44
 
ERK
 
 phosphor-
ylation is maximal), we found that prior treatment of cells with
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PIPLC had no significant effect (Fig. 3 A). However, if cells
were first exposed to FGF2, treated with or without PIPLC for
1 h, and reexposed to FGF2 for 15 min, MAPK activation was
substantially lower in the PIPLC-treated cells (Fig. 3 B).
These results suggest that when cells are first exposed to
FGF2, glypican-1 is not the only HSPG that can serve as an
FGF coreceptor, but FGF2 triggers an event that causes it to be-
come so later on. An obvious candidate for such an event
would be loss of syndecan-1 from the cell surface. Indeed, syn-
decan-1 (as well as other syndecans) is known to be shed from
cell surfaces through cleavage by endogenous proteases. More-
over, a variety of ligands can trigger such shedding, including
EGF and HB-EGF (Subramanian et al., 1997; Fitzgerald et al.,
2000), although in the only case in which FGF2 was examined
(a lymph node endothelial cell line), induced shedding of syn-
decan-1 was not seen (Subramanian et al., 1997).
To test whether FGF2 might cause PANC-1 cells to shed
their syndecan, we exposed cells to FGF2 for 30 min, washed,
and then used mild trypsin to release the ectodomains of what-
ever syndecan-1 remained on the cells; these were then quanti-
fied by immunoblotting. As shown in Fig. 4 A, FGF2 caused a
substantial reduction in syndecan-1 remaining on cell surfaces.
In three independent experiments, we observed a
 
 
 
mean de-
crease of 59 
 

 
 11%. This value is likely to be an underestimate
because the pool of trypsin-released syndecan-1 probably in-
cludes some molecules derived from dead cells, cell fragments,
or substratum-attached material that would not be expected to
respond to FGF2.
To test whether shedding of syndecan-1 plays a causal
role in its failure to act as a long-term FGF coreceptor, we
transfected PANC-1 cells with a mouse syndecan-1 in which
the juxtamembrane protease-sensitive site had been replaced
with a heterologous sequence. This form is known to resist
shedding by endogenous proteases (Fitzgerald et al., 2000). As
a control, we used wild-type mouse syndecan-1. As shown in
Fig. 4 B, substantial expression of both wild-type and cleavage
site–modified syndecan-1 could be detected in stably transfected
cell clones. As was the case with the endogenous sydecan-1, we
could readily detect FGF2-induced shedding of exogenous wild-
type mouse syndecan-1 but saw no evidence for shedding of
the cleavage mutant form (Fig. 4 C). When cells expressing
these constructs were tested for MAPK activation 1 h after
FGF2 addition, cells expressing cleavage-resistant syndecan-1
showed no inhibition by PIPLC, whereas the responses of cells
expressing wild-type syndecan-1, like sham-transfected cells,
were highly PIPLC sensitive (Fig. 4 D). Thus, when cells ex-
press a form of syndecan-1 that cannot be shed, long-term re-
sponses to FGF2 lose their glypican dependence.
Studies in rodent cells suggest that the enzymes respon-
sible for syndecan-1 shedding are members of the matrix me-
talloproteinase (MMP) family (Subramanian et al., 1997;
Figure 3. PIPLC blocks long-term but not short-term MAPK activation.
(A) Where indicated, PANC-1 cells were incubated with 1 U/ml PIPLC for
1 h. Serum-free medium containing 1 ng/ml FGF2 (with 1 U/ml PIPLC
where used) was added, and incubation continued for either 15 min or 1 h.
Cells were lysed, and activated MAPK (p42/44ERK) was detected by im-
munoblotting. As a control for protein loading, immunoblotting was per-
formed with an anti–-tubulin mAb. Results from duplicate cultures are
shown. (B) Cells were treated with FGF2 and analyzed as in A except that
some samples were also exposed to FGF2 during the 15 min before the
1-h PIPLC incubation. When such cells were subsequently reexposed to
FGF, short-term (15 min) MAPK activation was substantially PIPLC sensitive
(asterisk; P  0.02; t test). Data are duplicates  SEM (error bars). Y axis
is measured in arbitrary units.
Figure 2. PIPLC releases only a fraction of cell surface heparan sulfate.
PANC-1 cells metabolically labeled with [35S]sulfate were treated with or
without PIPLC, and the supernatant was collected. Cells of each type were
then incubated with or without TPCK-treated trypsin for 10 min on ice fol-
lowed by the addition of trypsin inhibitor and collection of the superna-
tant. In this way, labeled fractions released by no enzyme, PIPLC, trypsin,
and trypsin after PIPLC were obtained. To quantify protein-associated
GAGs in these fractions, aliquots were digested with heparinase III, chon-
droitinase ABC, or no enzyme followed by TCA precipitation. Specific re-
lease of heparan sulfate (solid bars) by PIPLC was defined as the differ-
ence between chondroitinase-resistant radioactivity released from cells
exposed and cells not exposed to PIPLC. The analogous calculations were
performed to measure the specific release of heparan sulfate by trypsin or
by trypsin after pretreatment with PIPLC. Similarly, the specific release of
chondroitin sulfate (dotted bars) was calculated as heparinase-resistant
radioactivity in the same fractions. Data are means  SD (error bars) for
duplicate experiments. Similar overall results were obtained when heparan
sulfate was calculated by subtracting the amount of radioactivity precipi-
tated by TCA after heparinase digestion from that precipitated from un-
digested supernatants. Likewise, similar results were obtained when
chondroitin sulfate was calculated by subtracting the amount of radioactivity
precipitated by TCA after chondroitinase digestion from that precipitated
from undigested supernatants.
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Fitzgerald et al., 2000; Li et al., 2002; Asundi et al., 2003). If
such enzymes also shed syndecan-1 in pancreatic carcinoma
cells, one might expect inhibitors of MMPs to cause FGF2 re-
sponses to lose glypican dependence. This is indeed the case.
As shown in Fig. 5 A, in PANC-1 cells, shedding of synde-
can-1 can be blocked by pretreatment with either the broad
spectrum MMP inhibitor GM6001 or TIMP-3, which is an en-
dogenous polypeptide inhibitor of MMPs. At the same time,
both GM6001 and TIMP-3 make the long-term FGF2 re-
sponse of PANC-1 cells insensitive to PIPLC (Fig. 5 B, top
two sets of blots). Results with GM6001 were not caused by any
direct inhibitory effect of this drug on PIPLC itself, as such a
possibility was assayed directly (using the PIPLC-mediated
release of alkaline phosphatase from appropriate cell lines;
not depicted).
Pancreatic carcinoma cells are not the only cells that dis-
play strong glypican dependence of growth factor signaling;
we reported similar behavior in several breast carcinoma cell
lines (Matsuda et al., 2001). Like PANC-1 cells, such breast
cancer cells express syndecan-1 (Matsuda et al., 2001). To
determine whether syndecan-1 shedding might underlie the
glypican dependence of these cells, we tested the effects of
MMP inhibition on the ability of PIPLC to abrogate FGF2-
mediated signaling. As shown in Fig. 5 B, MDA-MB-468
breast carcinoma cells behaved much like PANC-1 cells: long-
term (1 h) MAPK activation was blocked by prior PIPLC expo-
sure but could be completely rescued by GM6001. Fig. 5 B
also shows results from a nontransformed mouse myoblast cell
line (C2C12), which is known to express both syndecan-1 and
glypican-1 and to respond to FGF2 (Brandan et al., 1996; Larrain
et al., 1997). Unlike the tumor-derived cell lines, the long-term
FGF2 responses of these cells were not diminished by pre-
treatment with PIPLC, suggesting, perhaps, that they do not
undergo FGF2-induced syndecan shedding.
Recent studies have implicated MMP7 (matrilysin) as the
protease that mediates stimulated shedding of syndecan-1 (Li
et al., 2002), but some have argued that membrane-type (MT)
MMPs (MT1-MMP and MT3-MMP; Endo et al., 2003) or
nonmatrix-type metalloproteinases, such as members of the
ADAM (a disintegrin and metalloproteinase domain) family
(Holen et al., 2001), are actually responsible. Interestingly,
MMP7 is frequently overexpressed by pancreatic cancer cells
(Fukushima et al., 2001; Yamamoto et al., 2001; Crawford et
Figure 4. FGF2 induces shedding of syndecan-1, and an “unsheddable”
syndecan-1 makes FGF2 responses PIPLC resistant. (A) PANC-1 cells were
treated with or without 2 ng/ml FGF2 for 30 min. After washing, trypsin
was used to specifically release syndecan-1 ectodomains. Half of each
sample was digested with 8 mU/ml heparinase III and 0.1 U/ml chon-
droitinase ABC. Syndecan-1 ectodomains were detected by Western blot-
ting with mAb B-B4. Exposure times for the first and second lanes were
longer than for the third and fourth lanes. (B) PANC-1 cells were stably
transfected with expression constructs for wild-type mouse syndecan-1, an
engineered variant of mouse syndecan-1 that replaces the cleavage se-
quence required for shedding with a heterologous one, or empty expres-
sion vector. Multiple clones of each type were expanded and examined
by immunocytochemistry (not depicted) and Western blotting using mouse-
specific syndecan-1 mAb 281.2. Western blot results from three represen-
tative clones are shown. Lanes 1 and 2, sham transfected; lanes 3 and 4,
wild-type syndecan-1; lanes 5 and 6, cleavage mutant syndecan-1. (C)
PANC-1 cells stably transfected with wild-type or cleavage mutant mouse
syndecan-1 (from B) were treated with 2 ng/ml FGF2 for 30 min. After
rinsing, cells were treated with trypsin as in A, and the released material
was digested with 8 mU/ml heparinase III and 0.1 U/ml chondroitinase
ABC. Syndecan-1 core protein was measured as in B. (A–C) Arrowheads
show positions of molecular mass standards (in kD). (D) The three clones
shown in B were tested for MAPK activation 1 h after the addition of 1 ng/ml
FGF2. For both the sham-transfected and wild-type syndecan-1–trans-
fected clones, pretreatment with 1 U/ml PIPLC (for 1 h) dramatically re-
duced FGF signaling (P  0.02 in both cases; asterisks), whereas in the
clone-expressing cleavage mutant syndecan-1, no significant reduction
was seen. Data are from triplicate cultures for each condition and are nor-
malized to loading controls. Error bars represent SEM. Y axis is measured
in arbitrary units.
Figure 5. Inhibition of metalloproteinases protects cells from PIPLC inhibi-
tion of the FGF2 response. (A) Metalloproteinase inhibitors block FGF2-
induced shedding of syndecan-1. PANC-1 cells were treated with or with-
out 1M GM6001 or 500 ng/ml TIMP-3 for 1 h and with 2 ng/ml FGF2
for 30 min. Syndecan-1 remaining on cell surfaces was released with
trypsin, concentrated, digested with heparinase and chondroitinase, and
quantified by Western blotting with mAb B-B4 as in Fig. 4. Arrows show
molecular mass markers. (B) Metalloproteinase inhibition makes long-term
FGF2 responses of tumor cells PIPLC insensitive, whereas the FGF2 re-
sponses of a nontumor cell line are already insensitive to PIPLC. PANC-1
cells, MDA-MB-468 breast carcinoma cells, and C2C12 mouse myoblasts
were treated for 1 h with 1 M GM6001, 500 ng/ml TIMP-3, or no pro-
tease inhibitor as indicated. Cells were then cultured for 1 h in the presence
of 1 ng/ml FGF2 or no growth factor (control). FGF2  PIPLC cells were
also exposed to 1 U/ml PIPLC during both the first and second hours of incu-
bation. Cell lysates were probed for p42/44ERK activation as in Figs. 1–4.
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al., 2002; Nakamura et al., 2002). To determine whether
MMP7 mediates syndecan-1 shedding by PANC-1 cells and,
thereby, accounts for the glypican-1 dependence of growth fac-
tor signaling, we first treated PANC-1 cells with exogenous ac-
tive MMP7 and demonstrated that it is capable of releasing
syndecan-1 into the medium (Fig. 6 A). Significantly, MMP7
did not release detectable glypican-1 (not depicted). Next, we
showed that after treatment with exogenous MMP7, even
short-term (15 min) responses of PANC-1 cells to FGF2 be-
come PIPLC sensitive (Fig. 6 B). Thus, exposure to active
MMP7 mimics the effects of prior exposure to FGF2 (Fig. 3 B).
Control experiments verified that MMP7 does not itself degrade
FGF2 (not depicted).
To test whether FGF2 causes the activation of endoge-
nous cell surface MMP7, we took advantage of the fact that
MMP7 associates with cell surfaces by binding to GAGs and
can be specifically released by heparin (Yu and Woessner,
2000). Therefore, after treatment of PANC-1 cells with FGF2,
we probed heparin washes of cells with antibodies specific for
the precursor and active forms of MMP7. We detected both
pro- and active MMP7 on the surface of untreated cells and
found that the levels of both forms were lower after FGF2
treatment (Fig. 6 C). In contrast, when we examined what was
released by cells during growth factor exposure, we saw more
MMP7, especially the active form, in the material released
from FGF2-treated as opposed to untreated cells (Fig. 6 C).
These results suggest that FGF2 not only activates
MMP7 but that it causes newly activated MMP7 and some pro-
MMP7 to be released from the cell surface. This makes sense if
one recalls that cell surface MMP7 is associated with heparan
sulfate, that about half of the heparan sulfate on PANC-1 cells
exhibits the protease sensitivity of a syndecan (Fig. 2), and that
MMP7 cleaves syndecan-1. Newly activated MMP7 molecules
would thus be expected to induce their own shedding in associ-
ation with syndecan-1 ectodomains. We can show that this
occurs by collecting the material released by FGF2-treated
PANC-1 cells, immunoprecipitating syndecan-1, and probing
the immunoprecipitate with antibody to activated MMP7 (Fig.
6 D). The results confirm that MMP7–syndecan-1 ectodomain
complexes are specifically released when PANC-1 cells are
treated with FGF2.
Although these results demonstrate that FGF2 is sufficient
to activate MMP7 and that activated MMP7 is sufficient to ac-
count for both the shedding of syndecan-1 and the subsequent
glypican dependence of cell growth, they do not prove that
MMP7 is solely responsible for syndecan-1 shedding. Other pro-
posed syndecan-1 shedding enzymes are MT1-MMP, MT3-
MMP (Endo et al., 2003), and ADAM metalloproteinases
(Holen et al., 2001). One distinguishing feature of MMP7 is that
it associates with cell surfaces through binding to GAGs (Yu and
Woessner, 2000), whereas MT-MMPs and ADAMs are integral
membrane proteins. Accordingly, MMP7—but not MT-MMPs
or ADAMS—can be released by heparin. Therefore, we pre-
treated PANC-1 cells with heparin, washed, exposed the cells to
FGF2, and tested for the release of syndecan-1. As shown in Fig.
7 A, heparin pretreatment blocked the ability of cells to shed syn-
decan-1. FGF2 signaling was not itself inhibited by the heparin
pretreatment; in fact, such signaling became PIPLC insensitive
(i.e., glypican-1 independent), as would be expected if syndecan-1
were remaining on the cell surface (Fig. 7 B). These data argue
that the molecule responsible for syndecan-1 shedding and gly-
pican-1–dependent mitogenesis is heparin displaceable, as would
be expected for MMP7.
To establish definitively that this molecule is MMP7, we
took advantage of the fact that a mAb specific for mature
MMP7 has been shown to be function blocking (Wroblewski et
al., 2003). As shown in Fig. 7 C, pretreatment of PANC-1 cells
with this antibody abrogated the ability of PIPLC to inhibit the
long-term FGF2 response, whereas pretreatment with control
antibody had no effect.
Figure 6. MMP7 is activated by FGF2, causes syndecan-1 shedding, and
is sufficient to make FGF responses PIPLC sensitive. (A) Exogenous MMP7
causes shedding of syndecan-1. PANC-1 cells were treated with or with-
out 1 g/ml MMP7 for 30 min. The media were collected, concentrated,
and digested with 8 mU/ml heparinase III and 0.1 U/ml chondroitinase
ABC followed by SDS-PAGE and Western blotting with mAb B-B4. Synde-
can-1 is seen as a high molecular mass smear that is converted by
GAGases to a band of 80 kD apparent size. (B) When PANC-1 cells
are pretreated with MMP7, even short-term responses to FGF2 become
PIPLC sensitive. The responses of PANC-1 cells to a 15-min treatment with
FGF2 were measured as in Fig. 3 A except that where indicated, cells
were treated with 1 g/ml MMP7 30 min before the addition of PIPLC
(if used) and throughout the 15-min exposure to FGF2. In MMP7-treated
cells, MAPK activation was strongly decreased by PIPLC (P  0.01). (C)
FGF2 induces MMP7 activation and release from the cell surface. PANC-1
cells were exposed to 2 ng/ml FGF2 for 30 min. The medium was removed,
and cell surface MMP7 was released with 0.3 mg/ml heparin (in PBS).
After concentrating as in A, samples were subjected to SDS-PAGE and
Western blotting using a mixture of antibodies specific for human pro-
MMP7 and activated MMP7. The asterisk shows the increase in released
active MMP7 in response to FGF2 treatment. (A and C) Arrows on the
right show positions of molecular mass standards (in kD). (D) FGF2 re-
leases complexes of syndecan-1 and active MMP7. PANC-1 cells were
treated with 5 ng/ml FGF2 for 30 min. Medium was collected and immuno-
precipitated with antisyndecan-1 antibody, and precipitates were sub-
jected to SDS-PAGE and Western blotting for activated MMP7. Controls
consisted of immunoprecipitates from cells not treated with FGF2 or pre-
cipitation omitting antisyndecan antibody. The top two bands (asterisks) in
the antibody-containing samples are IgG heavy and light chains. The
lowest band is active MMP7 (arrow).
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The mechanisms by which growth factors activate pro-
MMP7 are diverse and still poorly understood, although they
all ultimately result in cleavage of a propeptide (Crabbe et
al., 1992). Interestingly, when one treats PANC-1 cells with
FGF2 in the presence of GM6001, one can see an increase in
the level of activated MMP7 (using an antibody specific for
this form of the enzyme) on the cell surface (Fig. 7 D). It
makes sense that the newly activated MMP7 remains on the
cell surface as opposed to being shed (Fig. 6 C) given that
GM6001 should prevent syndecan-tethered MMP7 from re-
leasing itself. That MMP7 becomes activated at all in the
presence of GM6001 tells us that its activation by FGF2 is not
mediated by another GM6001-sensitive metalloproteinase.
Thus, MMP7 appears to be the sole metalloproteinase that is
either directly or indirectly required for syndecan-1 shedding
in these cells.
 
Discussion
 
The aforementioned results argue that in PANC-1 pancreatic
carcinoma cells, both glypican-1 and syndecan-1 can act as
coreceptors for FGF2, but because FGF2 activates MMP7,
which, in turn, induces the shedding of syndecan-1, a sustained
mitogenic response requires glypican-1. This conclusion is
based on several observations. The FGF2 response of these
cells is not initially sensitive to the removal of GPI-anchored
proteins by PIPLC but becomes so after exposure to FGF2.
FGF2 induces syndecan-1 shedding and also induces the acti-
vation of MMP7. Active MMP7 causes syndecan-1 shedding
and by itself will render initial responses to FGF2 glypican de-
pendent. When syndecan shedding is blocked with GM6001,
TIMP-3, expression of a cleavage-resistant syndecan-1, deple-
tion of cell surface MMP7 with heparin, or immunological
blockade of MMP7, FGF2 responses no longer become glypi-
can dependent.
Although this study focuses on the FGF2 responses of
pancreatic carcinoma cells, it is likely that the phenomenon de-
scribed here has wider relevance. First, glypican dependence is
observed in the growth factor responses of breast cancer cells,
and it is abrogated by the metalloproteinase inhibitor GM6001
(Fig. 5 D). Second, long-term responses to multiple heparin-
binding growth factors (e.g., HB-EGF, HGF, and heregulins)
are glypican dependent in pancreatic and breast cancer cells,
and at least one of these factors (HB-EGF) is known to induce
syndecan-1 shedding in some cells (Subramanian et al., 1997).
Third, all four syndecans (not just syndecan-1) undergo shed-
ding, with metalloproteinase dependence established for the
shedding of syndecans-3 and -4 (Subramanian et al., 1997;
Asundi et al., 2003). Indeed, although syndecan-1 is the major
syndecan on PANC-1 cells, we can detect in these cells small
amounts of mRNA for syndecans-2, -3, and -4 (unpublished
data), raising the possibility that shedding of these syndecans
could be of quantitative significance.
It is interesting that even before exposure to FGF2, sub-
stantial mature (activated) MMP7 is detected on PANC-1
cells (Fig. 6 C). The fact that substantial syndecan-1 is also
present on the cell surface suggests that most of this MMP7 is
nonfunctional, which is presumably a result of complex for-
mation with an endogenous inhibitor (e.g., TIMP-1, which
pancreatic carcinoma cells frequently overexpress; Zhou et
al., 1998). Accordingly, when pro-MMP7 molecules are acti-
vated by exposure to FGF2, one might expect them to eventu-
ally become inhibited too. In agreement with this prediction,
when we treat PANC-1 cells with FGF2 in the presence of
GM6001 (Fig. 7 D) so that newly activated MMP7 is revers-
ibly blocked and then remove GM6001 after 1 h, we do not
observe an onset of syndecan-1 shedding (unpublished data).
This suggests that over the course of an hour, activated MMP7
molecules do become stably inactivated.
It is provocative that the one nontransformed cell type
studied here (C2C12 myoblasts) showed no evidence for glypi-
can dependence of long-term FGF2 signaling, suggesting that
growth factor–mediated syndecan shedding may be a phenom-
enon that is more common in tumor cells than in normal cells.
Figure 7. MMP7 is required for syndecan-1 shedding. (A) Syndecan-1
shedding activity can be removed from the cell surface by treatment with
heparin. PANC-1 cells were treated with or without 0.3 mg/ml heparin for
30 min. After washing twice with PBS, cells were exposed to 5 ng/ml
FGF2 for 30 min. Medium was collected and subjected to heparinase and
chondroitinase digestion as in Fig. 6 A. Samples were concentrated and
subjected to SDS-PAGE and Western blotting for syndecan-1, the core
protein of which appears at 80 kD (arrows show positions of molecular
mass markers in kD). Results from two independent tests are shown. (B)
Pretreatment with heparin rescues the PIPLC dependence of long-term FGF
signaling. PANC-1 cells were treated with heparin as in A and were
tested for the PIPLC dependence of long-term (1 h) FGF2 signaling as in
Fig. 3 A. Whereas PIPLC greatly diminished the MAPK response of control
cells (P  0.01; t test), the responses of heparin-treated cells were un-
changed (P  0.4). (C) Pretreatment with a neutralizing antibody to
MMP7 renders long-term FGF signaling PIPLC insensitive. PANC-1 cells
were tested for the PIPLC dependence of long-term (1 h) FGF2 signaling as
in Fig. 3 A, with antiactivated MMP7 or nonimmune antibody (both at 4
g/ml) added 1 h before FGF2. (D) Activation of MMP7 by FGF2 does
not require the action of a GM6001-sensitive metalloproteinase. PANC-1
cells were exposed to 1 M GM600l for 1 h. Then, either 5 ng/ml FGF2
or control medium was added along with 1 M GM6001 for 30 min. Cell
surface MMP7 was harvested by extraction with 0.3 mg/ml heparin (in
PBS), and samples were concentrated as in A. The presence of activated
MMP7 was detected by Western blotting as in Fig. 6 D. Band densities
are averaged from triplicate determinations  SD (error bars) from equal
numbers of cells and reveal a greater than twofold increase in activated
MMP7 (P  0.05; t test). (C and D) Y axis is measured in arbitrary units.
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If so, it increases the likelihood that the inhibition of glypican
function could be of therapeutic value in selectively inhibiting
tumor cell growth.
Our results add to an expanding list of studies on the
functions of cell surface HSPGs (Bernfield et al., 1999;
Lander and Selleck, 2000; Park et al., 2000; Perrimon and
Bernfield, 2000). The degree to which syndecans and glypi-
cans have similar versus different functions is a long-standing
question. Comparisons among heparan sulfate structures on
glypicans and syndecans on the same cells have failed to iden-
tify functionally relevant differences (Liu et al., 1996; Tumova
et al., 2000; Zako et al., 2003), yet in a variety of in vitro sys-
tems, syndecans have been seen to carry out functions that
glypicans cannot. For example, syndecan-1, but not glypican-1,
inhibits the invasive behavior of myeloma cells, which is a
function that maps to parts of the syndecan-1 core protein
(Liu et al., 1996; Langford et al., 2005). In contrast, there are
few direct examples of glypicans performing functions that
syndecans cannot. Recently, one group reported that glypi-
cans, but not syndecans, can support growth factor responses
of glioma-associated brain endothelial cells (Qiao et al.,
2003). It will be interesting to see whether, as in this study,
such specificity arises as a consequence of induced syndecan
shedding and, if so, whether MMP7 (which is not commonly
found at high levels in gliomas; Vince et al., 1999) or a different
protease is the culprit.
From a more general perspective, it is remarkable that the
in vivo effects of the loss of function of glypicans in man,
mice, frogs, and flies almost universally are abnormalities in
growth or growth factor signaling (Pilia et al., 1996; Jackson et
al., 1997; Tsuda et al., 1999; Grisaru et al., 2001; Desbordes
and Sanson, 2003; Galli et al., 2003), whereas syndecan
loss-of-function mutations influence cell adhesion, migration,
axon guidance, neuropeptide activities, and synaptic function
(Woods and Couchman, 2001; Bellin et al., 2002; Bhanot and
Nussenzweig, 2002; Ishiguro et al., 2002; Kaksonen et al.,
2002; Reizes et al., 2003; Steigemann et al., 2004) but only
rarely influence cell growth (Alexander et al., 2000). As more
genetic studies are undertaken, it will be interesting to see the
extent to which this dichotomy holds up and whether growth
factor–induced syndecan shedding explains some or all of it.
This study raises a number of questions concerning the
roles of HSPGs in tumor formation and progression. Although
it is widely accepted that overexpression of growth factors and
their receptors by cancer cells plays a pivotal role in tumor pro-
gression (Friess et al., 1996; Mendelsohn and Baselga, 2000;
Haddad et al., 2001; LeRoith and Roberts, 2003; Yu et al.,
2003), the up-regulation of HSPG coreceptors by at least some
tumor cells has only recently been appreciated (Kleeff et al.,
1998; Matsuda et al., 2001; Zhu et al., 2001; Nakatsura et al.,
2004). In part, this is because most early studies of HSPGs in
cancer focused on syndecan-1 and generally reported no in-
crease or even a decrease in its expression (Nackaerts et al.,
1997; Pulkkinen et al., 1997; Fujimoto and Kohgo, 1998; Wik-
sten et al., 2000, 2001; Harada et al., 2003). However, in pan-
creatic carcinoma cells, both syndecan-1 and glypican-1 are
highly up-regulated (Kleeff et al., 1998; Conejo et al., 2000;
Barbareschi et al., 2003). In view of the present data, it seems
likely that whatever advantage is afforded such cells by ex-
pressing syndecan-1, it comes from the shed, not the cell sur-
face, form of the molecule. Interestingly, Yang et al. (2002)
reported that the growth of human myeloma cells in vivo is
strongly enhanced when the cells are engineered to express a
constitutively shed form of syndecan-1. How shed syndecan-1
enhances tumor growth is unclear, but an attractive hypothesis
is that syndecan ectodomains influence the extracellular pro-
teolysis that is essential for tumor invasion and metastasis.
Kainulainen et al. (1998) found that syndecan-1 ectodomains
enhance proteolytic activities in wound fluids by protecting pro-
teases from their endogenous inhibitors. Moreover, the activity
of MMP7, which is strongly implicated in tumor progression
(Yamamoto et al., 2001) and metastasis (Wilson et al., 1997), is
stimulated by heparin (Yu and Woessner, 2000) and, therefore,
may be greater when MMP7 is complexed with syndecan-1.
Another intriguing possibility, suggested by the present
data, is that syndecan-1 shedding aids in transporting acti-
vated MMP7 away from tumor cells and into surrounding
stroma. Ordinarily, one might expect that MMP7, which so
strongly binds heparan sulfate, would not readily diffuse
away from tumor cells as a result of trapping by cell surface
and extracellular matrix HSPGs. By associating with syndecan-1
ectodomains (Fig. 6 D), MMP7 could avoid such trapping
and, thereby, act at a greater distance. Such a mechanism of
action is strikingly analogous to that demonstrated by Li et al.
(2002) for syndecan-1 ectodomains as promoters of the diffu-
sion of chemokines away from injured lung epithelial cells,
an essential step in leukocyte recruitment.
 
Materials and methods
 
Materials
 
Materials were purchased from the following companies: DME and Lei-
bovitz’ L-15 medium (MediaTech, Inc.); OptiMEM (Invitrogen); HBSS (Ir-
vine Scientific); FBS (Hyclone); penicillin–streptomycin solution and 
 
L
 
-glu-
tamine (Invitrogen); LipofectAMINE and Geneticin (G418; GIBCO BRL);
methyl-[
 
3
 
H]thymidine and [
 
35
 
S]sulfate (PerkinElmer); DEAE-Sephacel, PD-10
desalting columns, ECL blotting reagents, and HRP-conjugated anti–rabbit
antibodies (GE Healthcare); and Immobilon P (Millipore). Heparinase III
and chondroitinase ABC were purchased from Seikagaku; GM6001
(Galardin) was obtained from BIOMOL Research Laboratories, Inc.;
Texas red–conjugated goat anti–mouse IgG antibodies were obtained
from Jackson ImmunoResearch Laboratories; anti-p42/44
 
ERK
 
 (anti-ERK1/
ERK2) was purchased from Promega or Cell Signaling Technology (simi-
lar results were obtained with either reagent); PIPLC was obtained from
Invitrogen; recombinant human FGF2 was purchased from R&D Systems;
bovine FGF2 was isolated from cow brain (Lobb and Fett, 1984); mouse
anti–human syndecan-1 mAb (B-B4) was purchased from Serotec; anti–
 

 
-tubulin (D-10) was obtained from Santa Cruz Biotechnology, Inc.; and
monoclonal anti-myc (9E10) was purchased from Covance, Inc. Active
human MMP7 was obtained from Calbiochem, and antibodies to precur-
sor and active forms of MMP7 (mAbs 3315 and 3322, respectively) as
well as to TIMP-3 were obtained from Chemicon. A full-length mouse syn-
decan-1 expression plasmid and anti–mouse syndecan-1 mAb 281.2
were gifts from A. Rapraeger (University of Wisconsin, Madison, WI)
and R.D. Sanderson (University of Arkansas for Medical Sciences, Little
Rock, AR). A cleavage-resistant mouse syndecan-1 expression plasmid
(Fitzgerald et al., 2000) was obtained from the research group of the
late M. Bernfield (Harvard Medical School, Cambridge, MA). A con-
struct encoding full-length placental alkaline phosphatase was a gift from
J.L. Millan (Burnham Institute, La Jolla, CA).
 
 
 
All other reagents were ob-
tained from Sigma-Aldrich.
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Cell culture and transfection
 
PANC-1 cells were cultured in DME with 6% (vol/vol) FBS. MDA-MB-468
breast carcinoma cells were cultured in L-15 medium with 10% (vol/vol)
FBS. C2C12 myoblasts were cultured in DME with 15% FBS. Antibiotics
(100 U/ml penicillin G and 100 
 

 
g/ml streptomycin sulfate) were added
to all media. Cells were maintained at 37
 

 
C in a 5% CO
 
2
 
 atmosphere.
Stable transfection of full-length mouse syndecan-1, cleavage-resistant
mouse syndecan-1 (Fitzgerald et al., 2000), and pCDNA3.1/glyp1-VS-
VGTMR (Kleeff et al., 1998) into PANC-1 cells was performed using Lipo-
fectAMINE (Kleeff et al., 1998). After reaching confluence, cells were
split into complete medium with 1 mg/ml G418. 2–3 wk later, indepen-
dent clones were isolated. The expression of glyp1-VSVGTMR was evalu-
ated by immunostaining using anti-myc antibodies. The expression of
syndecan-1 was evaluated by immunostaining using anti–mouse synde-
can-1 mAb 281.2 and by immunoblotting of detergent extractable pro-
teoglycans. For the latter measurements, cells were extracted with 2%
Triton X-100, 0.15 M NaCl, 10 mM EDTA, 10 mM KH
 
2
 
PO
 
4
 
, pH 7.5,
along with 5 
 

 
g/ml BSA, 100 
 

 
g/ml PMSF, and 25 
 

 
g/ml 
 
N
 
-ethylmale-
imide (NEM). After centrifugation, supernatants were subjected to DEAE-
Sephacel purification and were eluted with 150, 250, and 750 mM
NaCl in 50 mM Tris-HCl, pH 8.0, at 4
 

 
C. The pool eluted by 750 mM
NaCl was desalted on PD-10 followed by lyophilization. The resulting
material was digested with 10 mU/ml heparinase III (37
 

 
C overnight in 3
mM Ca(OAc)
 
2
 
, 50 mM NaOAc, 50 mM Hepes, and 10 mM EDTA, pH
6.5) and chondroitinase ABC (20 mU/ml in 0.1 M Tris-HCl, 10 mM
EDTA, pH 7.3) and subjected to 4–20% gradient SDS-PAGE and immuno-
blotting using anti–mouse syndecan-1.
 
DNA synthesis assay
 
PANC-1 cells were cultured in 24-well plates (30,000 cells/well) and al-
lowed to attach for 24 h. After washing with HBSS, cells were switched to
serum-free medium containing 0.2% BSA (RIA grade; Sigma-Aldrich) for
48 h. Where indicated, cells were then treated with 8 mU/ml heparinase III
or 1 U/ml PIPLC for 1 h. 40 
 

 
Ci/ml methyl-[
 
3
 
H]thymidine was added to-
gether with FGF2 at the indicated concentrations in fresh serum-free medium
(containing fresh heparinase III and/or PIPLC, where used), and incubation
continued for 24 h. Monolayers were washed with PBS, fixed with metha-
nol, and washed with water. DNA was precipitated with 6% (wt/vol)
trichloroactic acid and, following a water wash, was extracted with 0.3 M
NaOH (Tanaka et al., 1992). Radioactivity was measured by scintillation
counting. By this assay, the EC
 
50
 
 for the PANC-1 response to FGF2 was
 

 
0.7 ng/ml.
 
MAPK assay
 
5 
 
	
 
 10
 
5
 
 PANC-1 or MDA-MB-468 cells were plated in 100-mm plates,
cultured until confluent, and switched to serum-free medium containing
0.1% BSA for 48 h. In studies with C2C12 cells, cultures were switched to
serum-free medium at 70% confluence for 16 h. Where indicated, cells
were exposed to reagents such as 1 U/ml PIPLC, 1 
 

 
M GM6001, or 0.3
mg/ml heparin in serum-free growth medium for 1 h (or as indicated), and
the medium was replaced with fresh serum-free medium containing FGF2
(plus PIPLC and/or GM6001 as indicated) for an additional period of
either 15 min or 1 h at 37
 

 
C. Cells were washed twice with cold HBSS
and lysed with PBS containing 0.2% (wt/vol) SDS, 0.5% (vol/vol) Triton
X-100, 0.5% (wt/vol) sodium deoxycholate, 100 
 

 
g/ml PMSF, 1 
 

 
g/ml
pepstatin A, 25 
 

 
g/ml NEM, 1 
 

 
g/ml aprotonin, 1 
 

 
g/ml leupeptin, 5 mM
EDTA, 50 mM NaF, 50 mM Na
 
4
 
P
 
2
 
O
 
7
 
, and 100 mM Na
 
3
 
VO
 
4
 
. Samples
were mixed with 0.25 vol of fivefold concentrated SDS-PAGE sample buffer
and heated to 95
 

 
C for 8 min. After centrifugation, samples were sub-
jected to 12% SDS-PAGE and transferred to
 
 
 
Immobilon P. Membranes
were incubated for 1 h or overnight with polyclonal rabbit anti–human
p42/44
 
ERK
 
 antibody, washed, and probed using HRP-conjugated anti–
rabbit IgG. Visualization of bands by ECL was performed according to
manufacturer’s instructions. To verify equal protein loading, blots were
washed and reprobed with anti–
 

 
-tubulin mAb (Leask and Stearns, 1998).
In cases in which statistical tests were applied to the data, p42/44
 
ERK
 
band intensities were always first normalized to 
 

 
-tubulin band intensities
from the same samples.
 
Measurement of trypsin- and PIPLC-sensitive pools of cell surface GAGs
 
Confluent cultures of PANC-1 cells were incubated in growth medium with
12.25 
 

 
M reduced sulfate for 1 h and were cultured for 24 h in reduced
sulfate medium containing 50 
 

 
Ci/ml [
 
35
 
S]sulfate. After washing with ice-
cold 0.5 mM EDTA–TBS (Subramanian et al., 1997), cells were incubated
for 30 min at RT in the presence or absence of 2 U/ml PIPLC (in 0.5 mM
EDTA–TBS), and the supernatant was collected. Cells were then incubated
for 10 min on ice with or without 10 g/ml tosylphenylchloroketone
(TPCK)-treated trypsin (in 0.5 mM EDTA–TBS) followed by the addition of
soybean trypsin inhibitor (50 g/ml final concentration). Supernatants
were subjected to digestion with either 8 mU/ml heparinase III, 0.1 U/ml
chondroitinase ABC, both enzymes, or no enzyme for 2 h at 37C fol-
lowed by TCA precipitation and scintillation counting.
Measurement of cell surface, shed syndecan-1, and MMP7
To quantify endogenous cell surface syndecan-1, PANC-1 cells were incu-
bated with 10 g/ml TPCK-treated trypsin for 10 min on ice (Subrama-
nian et al., 1997) followed by the addition of 50 g/ml soybean trypsin
inhibitor. Supernatants containing syndecan-1 ectodomains were digested
with a mixture of 8 mU/ml heparinase III and 100 mU/ml chondroitinase
ABC, subjected to SDS-PAGE, blotted, and probed using anti–human syn-
decan-1 (B-B4) mAb. To quantify shed syndecan-1, conditioned media
were desalted on a PD-10 column, concentrated by lyophilization, and
subjected to 4–20% SDS-PAGE. To quantify cell surface MMP7, cells were
treated with 0.3 mg/ml heparin (in PBS) for 30 min at 4C, and the su-
pernatant was collected, desalted on a PD-10 column, concentrated by
lyophilization, subjected to SDS-PAGE, blotted, and probed using mAbs
specific for either the precursor or active forms of human MMP7 as indi-
cated. To quantify shed MMP7, conditioned media were desalted, con-
centrated, subjected to SDS-PAGE, and analyzed by immunoblotting. To
detect MMP7 that is complexed with shed syndecan-1, conditioned media
were treated with 100 g/ml PMSF, 2.5 g/ml NEM, and antisyndecan-1
antibody B-B4 (1:200) overnight at 4C. Syndecan-1 antibody complexes
were precipitated with protein G–agarose beads, which were then
washed, boiled in SDS sample buffer containing 2% -mercaptoethanol,
and subjected to SDS-PAGE and immunoblotting for active MMP7.
Antibody blockade of MMP7
The proteolytic activity of MMP7 was inhibited using mAb 3322 (Chemicon)
as described previously (Wroblewski et al., 2003). In brief, cells were ex-
posed to antibody or control nonimmune antibody (purified mouse IgG) at
a final concentration of 4 g/ml in culture medium beginning 1 h before
exposure to FGF2.
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